SG11202100054YA - Methods to reduce complications of intra-articular steroid - Google Patents

Methods to reduce complications of intra-articular steroid

Info

Publication number
SG11202100054YA
SG11202100054YA SG11202100054YA SG11202100054YA SG11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA SG 11202100054Y A SG11202100054Y A SG 11202100054YA
Authority
SG
Singapore
Prior art keywords
intra
methods
reduce complications
articular steroid
articular
Prior art date
Application number
SG11202100054YA
Other languages
English (en)
Inventor
Sheue-Fang Shih
Po-Chun Chang
Ming-Ju Wu
Original Assignee
Taiwan Liposome Co Ltd
Tlc Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Co Ltd, Tlc Biopharmaceuticals Inc filed Critical Taiwan Liposome Co Ltd
Publication of SG11202100054YA publication Critical patent/SG11202100054YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202100054YA 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid SG11202100054YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695763P 2018-07-09 2018-07-09
US201962839231P 2019-04-26 2019-04-26
PCT/US2019/040794 WO2020014118A1 (en) 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid

Publications (1)

Publication Number Publication Date
SG11202100054YA true SG11202100054YA (en) 2021-02-25

Family

ID=67441711

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100054YA SG11202100054YA (en) 2018-07-09 2019-07-08 Methods to reduce complications of intra-articular steroid

Country Status (12)

Country Link
US (1) US12083138B2 (https=)
EP (1) EP3820479B1 (https=)
JP (1) JP7463306B2 (https=)
KR (2) KR20210031715A (https=)
CN (1) CN112469420A (https=)
AU (1) AU2019301542B2 (https=)
BR (1) BR112021000316A2 (https=)
CA (1) CA3105743A1 (https=)
SG (1) SG11202100054YA (https=)
TW (1) TWI857961B (https=)
WO (1) WO2020014118A1 (https=)
ZA (1) ZA202100604B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023019192A1 (en) * 2021-08-11 2023-02-16 Board Of Regents, The University Of Texas System Dry liposome formulations and related methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide
US20130296267A1 (en) * 2008-01-18 2013-11-07 Horst Kief Agent for intra-articular injection
US8956600B2 (en) 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
RU2660585C2 (ru) * 2012-02-10 2018-07-06 Тайвэн Липосом Компани, Лтд. Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
SI2854769T1 (sl) * 2012-07-05 2023-09-29 Taiwan Liposome Company, Ltd. Postopki za zdravljenje artritisa
TWI845973B (zh) 2015-01-21 2024-06-21 美商桑紐爾製藥公司 醫藥配方

Also Published As

Publication number Publication date
EP3820479B1 (en) 2026-03-11
AU2019301542A1 (en) 2021-02-25
JP2021532074A (ja) 2021-11-25
TWI857961B (zh) 2024-10-11
AU2019301542B2 (en) 2025-04-03
TW202007398A (zh) 2020-02-16
CA3105743A1 (en) 2020-01-16
JP7463306B2 (ja) 2024-04-08
EP3820479A1 (en) 2021-05-19
US12083138B2 (en) 2024-09-10
ZA202100604B (en) 2025-05-28
CN112469420A (zh) 2021-03-09
BR112021000316A2 (pt) 2021-04-06
KR20210031715A (ko) 2021-03-22
WO2020014118A1 (en) 2020-01-16
KR20250093579A (ko) 2025-06-24
US20210196733A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
IL289046A (en) Preparations and methods for inhibiting antigens of a certain lineage
EP3250211A4 (en) Novel process for preparation of glucocorticoid steroids
EP3233047A4 (en) Compositions and methods for improving the appearance of the skin
HK1245719A1 (en) Additive manufacturing of metallic structures
EP3229997A4 (en) Additive manufacturing of metallic structures
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
EP3242672A4 (en) Amnion derived therapeutic composition and process of making same
EP3102673A4 (en) Methods and compositions for treatment of a beta thalessemia
PL3221331T3 (pl) Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
EP3206705A4 (en) Stable injectable composition of bivalirudin and process for its preparation
MX2015016031A (es) Proceso para la preparacion de dehidroepiandrosterona y sus intermediarios.
PL3221332T3 (pl) Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
EP3279181A4 (en) Mixture of polymerizable compound and method for producing same
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
EP3215132A4 (en) Methods of administering amantadine compositions
EP3215140A4 (en) Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
EP3151351A4 (en) Improvements to sections of cable trays
EP3237424A4 (en) Process of making cenicriviroc and related analogs
HUE058627T2 (hu) Új eljárás nagy tisztaságú prosztaglandinok elõállítására
PT3368673T (pt) Composições e métodos para a produção de mirceno
EP3123173A4 (en) Methods for suppressing cancer by inhibition of tmcc3
EP3221351A4 (en) Methods and compositions for cancer treating conditions relating to over expressions of epha2
SG11202100054YA (en) Methods to reduce complications of intra-articular steroid
EP3618869A4 (en) COMPOSITIONS AND PROCEDURES RELATED TO XCT ANTIBODIES
EP3060546A4 (en) Processes for the preparation of unsaturated esters